Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.45    0.00 (0.00%)
Bid:
8.30
Ask:
8.60
Spread: 0.30 (3.614%)
Market Cap: £18.43m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Re Agreement

26 Jun 2007 07:02

Phytopharm PLC26 June 2007 Company Contact: U.K. Investor Relations Contact:Phytopharm plc FDDr Daryl Rees CEO David YatesMr Piers Morgan CFO Ben Atwell+44 1480 437 697 +44 207 831 3113www.phytopharm.com Collaboration and Licence Agreement with The Beijing Institute for novel memoryand concentration product GODMANCHESTER, Cambridgeshire, U.K. (26 June 2007) - Phytopharm plc (LSE: PYM)("Phytopharm" or the "Company") announces today a Collaboration and LicenceAgreement with The Beijing Institute, Academy of Military Medical Sciences ("TheBeijing Institute") for the development of novel functional foods andpharmaceuticals, including a product for memory and concentration. Under the terms of the Collaboration and Licence Agreement, Phytopharm and TheBeijing Institute will collaborate to progress The Beijing Institute's leadproduct for memory and concentration selected from its library of patentedcompounds derived from Traditional Chinese Medicine. The Collaboration andLicence Agreement also extends to certain other patented compounds that may haveutility in other disease areas including vascular disorders and stroke.Phytopharm has been granted an exclusive licence from The Beijing Institute todevelop and commercialize these products globally in return for royalty andmilestone payments to The Beijing Institute upon the achievement of certainpre-defined goals. Financial terms of the agreement are not disclosed. Traditional Chinese Medicines have been used for thousands of years and overthat time a wealth of knowledge and expertise in the medicinal use of plants hasbuilt up. The Beijing Institute scientists have extensive knowledge ofTraditional Chinese Medicines and their research over the last 10 years has ledto the identification of a lead product that has the potential to improve memoryand concentration. Phytopharm will develop this lead product through furtherpre-clinical testing and progress into clinical trials. Commenting on today's announcement, Dr Xiaoming Yang, Head of The BeijingInstitute, said: "We are delighted to be working with Phytopharm and proud thatThe Beijing Institute's extensive expertise and experience in TraditionalChinese Medicine has been recognized by Phytopharm and we look forward to a longand fruitful collaboration." Commenting on today's announcement, Dr Daryl Rees, Chief Executive Officer ofPhytopharm, said: "We are excited about the Collaboration and Licence Agreementwith The Beijing Institute as it fulfils one of our strategic objectives ofexpanding our product portfolio with a novel functional food candidate formemory and concentration, an area in which we have established expertise. TheBeijing Institute's scientists bring significant knowledge on TraditionalChinese Medicine and we look forward to working with them to advance the leadproduct through clinical development." -Ends- Notes to Editors Phytopharm plc Phytopharm is a pharmaceutical development and functional food company whoseproduct leads are generated from medicinal plants. The Company's strategy is todevelop these products through 'proof of principle' clinical testing, and thensecure partners for late stage development, sales and marketing. Laboratory,manufacturing and clinical work is outsourced to selected specialists, operatingunder expert in-house management. This operational structure allows access tothe best external research facilities whilst maintaining low fixed overheads anda lower development cost structure. Beijing Institute The Beijing Institute (Institute of Radiation Medicine, the Academy of MilitaryMedical Sciences, Beijing) has over the past 50 years developed its researchstrengths from radiobiology into a wide range of scientific fields, includingbiotechnology, biochemistry, molecular biology, pharmaceutical chemistry,pharmacology, toxicology, experimental pathology, experimental haematology,genomics and proteomics. These groups were set up to provide the qualitycontrol for Traditional Chinese Medicine products and the identification anddevelopment of extracted active compounds. The Institutes considerableexpertise and experience in the extraction of active compounds from TraditionalChinese Medicine has resulted in several pharmaceutical products beingsuccessfully developed for the Chinese market. Functional Foods Functional foods are foodstuffs that provide health or physiological benefitsabove their nutritional value and have a health claim on the packaging.Currently gut and heart health products dominate with new interest in areas ofweight control, memory and concentration, immune system function and skinhealth. The global value of functional foods is estimated to be up to $65bn.The growth potential is predicted to be 50% from 2005-2010 with an acceleratingtrend for new products. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Mar 200611:47 amRNSNotice of Results
17th Mar 20068:53 amRNSBlocklisting Interim Review
30th Jan 20064:41 pmRNSSecond Price Monitoring Extn
30th Jan 20064:40 pmRNSPrice Monitoring Extension
24th Jan 20062:40 pmRNSResult of AGM
9th Jan 20067:01 amRNSRe: Agreement
4th Jan 20061:20 pmRNSHolding(s) in Company
15th Dec 200511:32 amRNSDirector/PDMR Shareholding
30th Nov 20053:30 pmRNSBoard Change
28th Nov 20053:03 pmRNSResearch Update
15th Nov 20057:02 amRNSResearch Update
4th Nov 200512:50 pmRNSDirector/PDMR Shareholding
4th Nov 200512:47 pmRNSDirector/PDMR Shareholding
4th Nov 200512:45 pmRNSBlocklisting Interim Review
4th Nov 200512:15 pmRNSBoard Change
2nd Nov 20057:00 amRNSFinal Results
30th Sep 20057:01 amRNSResearch Update
28th Sep 20052:19 pmRNSNotice of Results
23rd Sep 20052:09 pmRNSBlocklisting Interim Review
30th Jun 200510:38 amRNSHolding(s) in Company
23rd Jun 20057:02 amRNSChange of Broker
16th Jun 20055:26 pmRNSBlocklisting Interim Review
16th May 20057:00 amRNSHolding(s) in Company
13th May 20051:59 pmRNSHolding(s) in Company
12th May 20055:10 pmRNSDirector Shareholding
12th May 20055:06 pmRNSDirector Shareholding
12th May 20054:59 pmRNSDirector Shareholding
11th May 20057:01 amRNSInterim Results
10th May 20057:00 amRNSHolding(s) in Company
4th May 200511:00 amRNSOpen Offer Take Up
29th Apr 20052:39 pmRNSBlocklisting Interim Review
20th Apr 200512:06 pmRNSHolding(s) in Company
19th Apr 20054:04 pmRNSNotice of Results
8th Apr 20057:01 amRNSPlacing and Open Offer
29th Mar 20059:30 amRNSRe Agreement
21st Mar 200510:56 amRNSBlocklisting Interim Review
8th Mar 20057:01 amRNSHolding(s) in Company
8th Mar 20057:00 amRNSHolding(s) in Company
1st Mar 20052:57 pmRNSHolding(s) in Company
28th Feb 20057:03 amRNSRe Agreement
25th Feb 20051:21 pmRNSEGM Statement
24th Feb 20053:32 pmRNSResults Placing & Open Offer
2nd Feb 20057:01 amRNSOpen Offer
26th Jan 200512:22 pmRNSStmnt re Share Price Movement
20th Jan 20057:01 amRNSResearch Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.